Pharmaceuticals in society

Green and Sustainable Pharmacy

Volumn , Issue , 2010, Pages 23-35

  Triggle, David J ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b Center for Inquiry   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78049254510     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-642-05199-9_3     Document Type: Chapter

References (78)

1. Adam D (2009) Down on the pharm. The Guardian, April 30. www.guardian.co.uk. Accessed July 24, 2009
2. Angell M (2004) The Truth About Drug Companies. Random House, New York
3. Associated Press (2008) Pharmawater. 1. March 9. http://nl.newsbank.com
4. Arrow KJ (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev LIII, 941-973
5. Baker D (2008) Getting more for less. The not-so-obvious benefit of publicly funded trials for new drugs. The Milken Institute Review, Third Quarter, 46-53
6. Brandt AM (2007) The Cigarette Century. Perseus Books, New York
7. Bray GA, Tartaglia LA (2000) Medicinal strategies in the treatment of obesity. Nature 404, 672-677
8. Brookes M (2004) Extreme Measures. Bloomsbury Books, London
9. Burd-Sharps S, Lewis K, Martins EB (2008) The Measure of America. American Human Development Report, 2008-2009. Columbia University Press, New York
10. Butler D (2007) Neglected diseases. Nature 449, 157-182
11. Callahan D, Wasunna AA (2006) Medicine and the Market. Equity v. Choice. Johns Hopkins University Press, Baltimore, MD
12. Commonwealth Fund (2007) Mirror, mirror on the wall: An international update on the comparative performance of American health care. www.commonwealthfund.org
13. Commonwealth Fund (2008) Why not the best? Results from the national scorecard on U.S. health system performance, 2008. www.commonwealthfund.org
14. Couzin-Frankel J (2009) The promise of a cure: 20 years and counting. Science 324, 1504-1507
15. Cuatrecasas P (2006) Drug discovery in jeopardy. J Clin Invest 116, 2837-2842
16. Danzon PM (2007) At what price? Nature 449, 176-180
17. De Angelis C, et al. (2004) Clinical trial registration: A statement from the International Committee of Medical Journal Editors. N Engl J Med 352, 2436-2438
18. Dean C (2007) Drugs are in the water. Does it matter? New York Times, April 3. www.nytimes.com
19. DiMasi JA, Hansen RW, Grabowski HG (2003) J Health Econ 22, 151-185
20. Editorial Nature Biotechnology (2004) Drugs in crops-the unpalatable truth. Nat Biotechnol 22,∼133
21. Ehrlich P (1959) Papers reprinted in the collected papers of Paul Ehrlich. In: Himmelweit F, Marquardt M, Dale HH (eds.) Chemotherapy 3. Pergamon Press, Press, London, pp. 505-518
22. European Commission for Competition EU competition inquiry into pharmaceutical sector. www.Ec.europa.eu/commission. Accessed July 27, 2009
23. Farmer P (1999) Infections and Inequalities. The Modern Plagues. California University Press, Berkeley, CA
24. Finkelstein S, Temin P (2008) Reasonable Rx: Solving the Drug Price Crisis. FT Press, London and New York
25. Food I (2009) www.foodincmovie.com. Accessed July 27, 2009
26. Friedman JM (2000) Obesity in the new millennium. Nature 404, 632-634
27. General Accounting Office (2006) New Drug Development. Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts. GAO-07-49.www.gao.gov
28. Grabowski H (2008) Follow-on biologics: Data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov 7, 479-488
29. Gross L (2007) The toxic origins of disease. PLoS Biol 5, e193
30. Hegde BM (2005) Modern medicine-A boon or a bane. Kuwait Med J 37, 235-237, December
31. Heller M (2008) Gridlock Economy. How Too Much Ownership Wrecks Markets, Stops Innovation and Costs Lives. Basic Books, New York
32. Heller M, Eisenberg RS (1998) Can patents deter innovation? The anti-commons in biomedical research. Science 280, 698-701
33. Hellerstein MK (2008) A critique of the molecular target-based drug discovery paradigm based on principles of metabolic control. Advantages of pathway-based drug discovery. Metab Eng 10, 1-9
34. Herrling P (2006/2007) Building innovative partnerships in neglected disease research. Drug Discov World, 22-25, Winter
35. Hertzman C (2001) Health and human society. Am Sci 89, 538-545
36. Johnson S (2006) The Ghost Map. Riverhead Books, New York
37. Huxley A (1932) Brave New World. Harper Row, New York
38. Judson H (1979) The Eighth Day of Creation: Makers of the Modern Revolution in Biology. Simon and Schuster, New York
39. Karlberg JPE (2008) Trends in disease focus of drug development. Nat Rev Drug Discov 7, 639-640
40. Kopelman PG (2000) Obesity as a medical problem. Nature 404, 635-643
41. Ledford H (2007) The same but different. Nature 449, 274-276
42. Leranth C, Hajszan T, Szigeti-Buck K, Bober J, MacLusky NJ (2008) Bisphenol a prevents the synaptogenic response to estradiol in hippocampus and prefrontal cortex of ovariectomized nonhuman primates. Proc Natl Acad Sci USA 105, 14187-14191
43. Li JE-H, Vederas JC (2009) Drug discovery and natural products: End of an era or an endless frontier? Science 325, 161-165
44. Manheim BS, Jr, Ranahan P, Dow KJ (2006) "Follow-on biologics": Ensuring continued innovation in the biotechnology industry. Health Affairs 26, 394-404
45. McKibben B (2003) Enough. Staying human in an engineered age. Holt and Company, New York
46. Medecins sans Frontier (2001) Fatal Imbalance. The crisis in research and development for drugs for neglected diseases. www.access.med-msf.org, http://www.msf.org
47. Mello MM, Studdert DM, Brennan TA (2006) Obesity-the new frontier of public health law. N Engl J Med 354, 2601-2610
48. Moynihan R, Cassels A (2005) Selling Sickness. Nation Books, New York
49. Moynihan R (2006) Scientists find new disease: Motivational deficiency disorder. BMJ 332, 745
50. Moynihan R (2008) Disease mongering is now part of the global health debate. PLoS Med 5, 0684-0686
51. Nestle M (2006) Food marketing and childhood obesity-a matter of policy. N Engl J Med 354, 2527-2529
52. Noble D (2008) Claude Bernard, the first systems biologist, and the future of physiology. Exp Physiol 93, 16-26
53. Nolte E, McKee CM (2008) Measuring the health of nations: Updating an earlier analysis. Health Affairs 27, 58-71
54. Pew Charitable Trust (2008) One in 100: Behind bars in America 2008. www.pewtrusts.org
55. Pollack A (2009) Costly drugs known as biologics promote exclusivity debate. New York Times, July 22, 2009. www.nytimes.com. Accessed July 25, 2009
56. Roberts L, Simpson S (2008) Deadly defiance. A series of articles on drug resistance. Science 321, 355-369
57. Sachs JD (2005) The End of Poverty. Economic Possibilities for Our Time. Penguin Press, New York
58. Schlosser E (2001) Fast Food Nation. The Dark Side of the All-American Meal. Houghton Miflin, New York
59. Schmid EF, Smith DA (2007) Pharmaceutical R&D in the spotlight: Why is there still unmet medical need? Drug Discov Today 12, 998-1006
60. Smith JS (1990) Patenting the Sun. Polio and the Salk Vaccine. William Morrow, New York
61. Srinivas KR (2006a) TRIPS, access to medicines and developing nations. Towards an open source solution. Working paper no. 248. Indian Institute of management, Bangalore, India. www.policyinnovations.org/ideas/policy-library/ data/01492-35-k
62. Srinivas KR (2006b) Intellectual property rights and biocommons: Open source and beyond. UNESCo. www.unesco.org
63. Satrfield B (2000) Is US health really the best in the world? JAMA 284, 483-485
64. Stuckler D, King LP, Basu S (2008) International monetary fund programs and tuberculosis outcomes in post-communist countries. PLoS Med 5, 1079-1090
65. Svoboda E (2008) Old McDonald had a Pharm. Salon, June 11. www.salon.com
66. Taubes G (2009) Prosperity's plague. Science 325, 256-260
67. Triggle DJ (2003) Medicines in the 21st Century. Drug Dev Res 59, 269-291
68. Triggle DJ (2005a) Vaccines, viagra and vioxx: Medicines, markets and money-when life-saving meets life-style. Drug Dev Res 64, 90-98
69. Triggle DJ (2005b) Patenting the sun: Enclosing the scientific commons and transforming the university-ethical concerns. Drug Dev Res 63, 139-149
70. Triggle DJ (2006) Treating desires not diseases: A pill for every ill and an ill for every pill? Drug Discov Today 12, 161-166
71. Triggle DJ (2009) The chemist as astronaut: Searching for biologically useful space in the chemical universe. Biochem Pharmacol 78, 217-223
72. Tucker TJ, Makgoba MW (2008) Public-private partnerships and scientific imperialism. Science 320, 1016-1017
73. Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM (2009) Bisphenol-A and the great divide: A review of controversies in the field of endocrine disruption. Endocrine Reviews 30, 75-95
74. Wadman M (2005) Path to approval proves rocky for copycat biodrugs. Nature 438, 154-155
75. Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24, 1241-1252
76. Wilkinson RG (2000) Mind the Gap. Hierarchies, Health and Evolution. Yale University Press, New Haven
77. Wilkinson RG, Pickett KE (2006) Income inequality and population health: A review and explanation of the evidence. Social Sci Med 62, 1768-1784
78. Williams M (2004) A return to the fundamentals of drug discovery? Curr Opin Invest Drugs 5, 29-33